2. Search Result
Search Result
Results for "

PDGFR-IN-1

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-144653
    PDGFR-IN-1

    		PDGFR Apoptosis Cancer
    PDGFR-IN-1 (compound 7m) is a potent and orally active PDGFR (platelet-derived growth factor receptor) inhibitor, with IC50 values of 2.4 and 0.9 nM for PDGFRα and PDGFRβ, respectively. PDGFR-IN-1 displays robust antitumor effects and low toxicity, and can be used to study osteosarcoma [1].
    PDGFR-IN-1
  • HY-10337
    Brivanib
    3 Publications Verification

    BMS-540215

    		 VEGFR Autophagy Cancer
    Brivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β .
    Brivanib
  • HY-10336
    Brivanib (alaninate)
    3 Publications Verification

    BMS-582664

    		 VEGFR Autophagy Cancer
    Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ .
    Brivanib (alaninate)
  • HY-169520
    VEGFR/PDGFR-IN-1

    		VEGFR Cancer
    VEGFR/PDGFR-IN-1 (Compound 1) is the inhibitor for VEGFR with an IC50 of 0.4 μM. VEGFR/PDGFR-IN-1 inhibits angiogenesis in HUVEC cell, exhibiting potential in tumor growth and metastasis inhibition [1].
    VEGFR/PDGFR-IN-1
  • HY-123392
    Sch 13835

    		PDGFR Cardiovascular Disease
    Sch 13835 is a platelet-derived growth factor (PDGFR) inhibitor .
    Sch 13835
  • HY-167869
    A-849529

    		Drug Metabolite Others
    A-849529 is an acid metabolite of ABT-869 (HY-50751). ABT-869 is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family .
    A-849529
  • HY-161843
    Necroptosis-IN-4

    		Necroptosis RIP kinase Inflammation/Immunology
    Necroptosis-IN-4, a potent necroptosis inhibitor, is a RIP kinase 1 (RIPK1) inhibitor. Necroptosis-IN-4 has no inhibitory activity against RIPK3 and weak inhibitory activity against VEGFR1/2 and PDGFR-α .
    Necroptosis-IN-4
  • HY-10337R
    Brivanib (Standard)

    BMS-540215 (Standard)

    		 Reference Standards VEGFR Autophagy Cancer
    Brivanib (Standard) is the analytical standard of Brivanib. This product is intended for research and analytical applications. Brivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β .
    Brivanib (Standard)
  • HY-10336R
    Brivanib (alaninate) (Standard)

    BMS-582664 (Standard)

    		 Reference Standards VEGFR Autophagy Cancer
    Brivanib (alaninate) (Standard) is the analytical standard of Brivanib (alaninate). This product is intended for research and analytical applications. Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ .
    Brivanib (alaninate) (Standard)
  • HY-W758126
    (R)-Brivanib alaninate-d4

    		Isotope-Labeled Compounds Others
    (R)-Brivanib alaninate-d4 is the deuterium-labeled Brivanib (alaninate) (HY-10336). Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ .
    (R)-Brivanib alaninate-d4
  • HY-21291
    SU-4313

    		PDGFR EGFR IGF-1R Cancer
    SU-4313 is a potent protein tyrosine kinases (PTKs) modulator with IC50s of 14.5 μM, 18.8 μM, 11 μM, 16.9 μM, 8.0 μM for PDGFR, FLK-1, EGFR, HER2 Kinase and IGF-1R, respectively. SU-4313 has the potential for modulating tyrosine kinase signal transduction in order to regulate abnormal cell proliferation [1].
    SU-4313
  • HY-100349
    SU4312

    		PDGFR VEGFR Cancer
    SU4312 is the racemate of (Z)-SU4312 and (E)-SU4312. (Z)-SU4312 inhibits PDGFR and FLK-1 with IC50s of 19.4 and 0.8 μM, respectively. (E)-SU4312 inhibits PDGFR, FLK-1, EGFR, HER-2, and IGF-1R with IC50s of 24.2, 5.2, 18.5, 16.9 and 10.0 μM, respectively [1].
    SU4312
  • HY-100349A
    cis-SU4312

    (Z)-SU4312

    		 PDGFR VEGFR Cancer
    cis-SU4312 ((Z)-SU4312) inhibits PDGFR and FLK-1 with IC50s of 19.4 and 0.8 μM, respectively. cis-SU4312 inhibits PDGFR, FLK-1, EGFR, HER-2, and IGF-1R with IC50s of 24.2, 5.2, 18.5, 16.9 and 10.0 μM, respectively. cis-SU4312 can cross blood brain barrier [1].
    cis-SU4312

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: